Omnicell (NASDAQ:OMCL) Shares Gap Down – What’s Next?

Omnicell, Inc. (NASDAQ:OMCL) shares gapped down before the market opened on Wednesday . The stock had previously closed at $35.71, but opened at $33.92. Omnicell shares last traded at $34.07, with a volume of 60,518 shares.

Wall Street Analyst Weigh In

Several research firms have recently commented on OMCL. Bank of America reduced their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Benchmark reiterated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. lifted their target price on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, March 6th. Finally, Wells Fargo & Company dropped their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $52.33.

Omnicell Price Performance

The stock’s fifty day moving average price is $40.96 and its 200-day moving average price is $43.38. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a market cap of $1.51 billion, a PE ratio of 119.56, a P/E/G ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently made changes to their positions in OMCL. Smartleaf Asset Management LLC boosted its position in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after buying an additional 273 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in Omnicell during the 4th quarter worth about $37,000. Van ECK Associates Corp increased its position in Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Omnicell during the 4th quarter worth about $53,000. Finally, First Horizon Advisors Inc. increased its position in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after purchasing an additional 355 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.